title: Human anti-mouse IgM and IgG responses in ovarian cancer patients after radioimmunotherapy with 90Y-muHMFG1.
abstract: BACKGROUND
  Human anti-mouse antibody (HAMA)-IgM and IgG in ovarian cancer patients treated with intraperitoneal (i.p.) 90Y-muHMFG1 as consolidating therapy were analyzed for a relationship with outcome of disease.
  
  
  METHODS
  Serial serum samples from 208 ovarian cancer patients participating in a phase III trial of i.p. 90Y-muHMFG1 and 25 controls were analyzed for HAMA-IgM and HAMA-IgG. Results were correlated with time to, and location of, disease recurrence.
  
  
  RESULTS
  Patients receiving i.p. 90Y-muHMFG1 developed a rapid HAMA-IgM peak (week 4 to 8), followed by a HAMA-IgG peak 2-4 weeks later. HAMA levels in the control group remained unchanged. Early maximum HAMA-IgG peaks were associated with early relapse [hazard ratio (HR), 0.975; 95% confidence interval (CI) 0.956 to 0.995; p=0.012]. Patients with a HAMA-IgG maximum before or at 8 weeks were at significantly higher risk for disease recurrence (HR, 1.6; 95% CI 1.1 to 25;p=0.021) as compared to patients with a HAMA-IgG maximum after 8 weeks.
  
  
  CONCLUSIONS
  Besides time point of maximum HAMA-IgG, no evident relation could be found between HAMA-IgM or HAMA-IgG development and time to relapse or location of recurrence.
authors.affiliation: Department of Obstetrics and Gynecology, Radboud University Nijmegen Medical Centre, the Netherlands.
authors.forename: Angèle L M
authors.initials: AL
authors.lastname: Oei
authors.forename: Fred C G J
authors.initials: FC
authors.lastname: Sweep
authors.forename: Anneke
authors.initials: A
authors.lastname: Geurts-Moespot
authors.forename: Doorlène
authors.initials: D
authors.lastname: van Tienoven
authors.forename: Silvia
authors.initials: S
authors.lastname: Von Mensdorff-Pouilly
authors.forename: Chris M G
authors.initials: CM
authors.lastname: Thomas
authors.forename: Leon F A G
authors.initials: LF
authors.lastname: Massuger
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018572:Disease-Free Survival; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis* / Q000097:blood / Q000276:immunology; D007075:Immunoglobulin M / Q000096:biosynthesis* / Q000097:blood / Q000276:immunology; D000922:Immunotoxins / Q000627:therapeutic use*; D051379:Mice; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000276:immunology* / Q000532:radiotherapy*; D016499:Radioimmunotherapy; D055815:Young Adult; D015021:Yttrium Radioisotopes / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D000922:Immunotoxins; D015021:Yttrium Radioisotopes; C469215:pemtumomab